Small animal imaging in drug development

Martin G. Pomper, Jae Sung Lee

Research output: Contribution to journalReview articlepeer-review

Abstract

Better mechanistic understanding of disease through mapping of the human and mouse genomes enables rethinking of human infirmity. In the case of cancer, e.g., we may begin to associate disease states with their underlying genetic defects rather than with the organ system involved. That will enable more selective, nontoxic therapies in patients who are genetically predisposed to respond to them. Because one of the major goals of molecular imaging research is to interrogate gene expression noninvasively, it can impact greatly on that process. Most of molecular imaging research is undertaken in small animals, which provide a conduit between in vitro studies and human clinical imaging. We are fortunate to be able to manipulate small animals genetically, and to have increasingly better models of human disease. The ability to study those animals noninvasively and quantitatively with new, high-resolution imaging devices provides the most relevant milieu in which to find and examine new therapies.

Original languageEnglish (US)
Pages (from-to)3247-3272
Number of pages26
JournalCurrent pharmaceutical design
Volume11
Issue number25
DOIs
StatePublished - 2005

Keywords

  • Drug development
  • Gene expression imaging
  • Molecular imaging
  • PET
  • Small animal imaging

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Small animal imaging in drug development'. Together they form a unique fingerprint.

Cite this